SEC Comment Letter 0000000000-23-001270 to Comera Life Sciences Holdings, Inc. (CMRA) (CIK 0001907685)

Comera Life Sciences Holdings, Inc. (CMRA) (CIK 0001907685)
Date: Feb. 7, 2023 · CIK: 0001907685 · Accession: 0000000000-23-001270

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-269564

Date

February 7, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Comera Life Sciences Holdings, Inc. (CMRA) (CIK 0001907685)

Letter

United States securities and exchange commission logo February 7, 2023 Jeffrey S. Hackman President and Chief Executive Officer Comera Life Sciences Holdings, Inc. 12 Gill Street, Suite 4650 Woburn, Massachusetts 01801 Re:Comera Life Sciences Holdings, Inc. Registration Statement on Form S-1 Filed February 3, 2023 File No. 333-269564 Dear Jeffrey S. Hackman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan M. Rourke Reed, Esq.

Show Raw Text

United States securities and exchange commission logo
February 7, 2023
Jeffrey S. Hackman
President and Chief Executive Officer
Comera Life Sciences Holdings, Inc.
12 Gill Street, Suite 4650
Woburn, Massachusetts 01801
Re:Comera Life Sciences Holdings, Inc.
Registration Statement on Form S-1
Filed February 3, 2023
File No. 333-269564
Dear Jeffrey S. Hackman:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Ryan M. Rourke Reed, Esq.

SecProbe.io